Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 43308

1.

Pretreatment neutrophil-to-lymphocyte ratio predicts prognosis in patients with metastatic renal cell carcinoma receiving targeted therapy.

Zhang GM, Zhu Y, Gu WJ, Zhang HL, Shi GH, Ye DW.

Int J Clin Oncol. 2015 Sep 3. [Epub ahead of print]

PMID:
26335242
2.

FDG and FLT-PET for Early measurement of response to 37.5 mg daily sunitinib therapy in metastatic renal cell carcinoma.

Horn KP, Yap JT, Agarwal N, Morton KA, Kadrmas DJ, Beardmore B, Butterfield RI, Boucher K, Hoffman JM.

Cancer Imaging. 2015 Sep 3;15(1):15.

PMID:
26335224
3.
4.

Molecular genetics and clinical features of Birt-Hogg-Dubé syndrome.

Schmidt LS, Linehan WM.

Nat Rev Urol. 2015 Sep 1. doi: 10.1038/nrurol.2015.206. [Epub ahead of print] Review.

PMID:
26334087
5.

Transcriptional and post-translational modifications of B-Raf in quinol-thioether induced tuberous sclerosis renal cell carcinoma.

Cohen JD, Labenski M, Mastrandrea NJ, Canatsey RD, Monks TJ, Lau SS.

Mol Carcinog. 2015 Aug 31. doi: 10.1002/mc.22366. [Epub ahead of print]

PMID:
26333016
6.

miR-372 suppresses tumour proliferation and invasion by targeting IGF2BP1 in renal cell carcinoma.

Huang X, Huang M, Kong L, Li Y.

Cell Prolif. 2015 Oct;48(5):593-9. doi: 10.1111/cpr.12207.

PMID:
26332146
7.

Clinicopathological characteristics and oncological outcomes in patients with renal cell carcinoma registered in 2007: The first large-scale multicenter study from the Cancer Registration Committee of the Japanese Urological Association.

Kanayama HO, Fukumori T, Fujimoto H, Nakanishi H, Ohyama C, Suzuki K, Nishiyama H, Eto M, Miki T, Kamoi K, Kubota Y, Takahashi S, Homma Y, Naito S.

Int J Urol. 2015 Sep;22(9):S1-7. doi: 10.1111/iju.12826.

PMID:
26332059
8.

Role of a serum-based biomarker panel in the early diagnosis of lung cancer for a cohort of high-risk patients.

Yang DW, Zhang Y, Hong QY, Hu J, Li C, Pan BS, Wang Q, Ding FH, Ou JX, Liu FL, Zhang D, Zhou JB, Song YL, Bai CX.

Cancer. 2015 Sep 1;121 Suppl 17:3113-21. doi: 10.1002/cncr.29551.

PMID:
26331818
9.

Clinical Trial Participants With Metastatic Renal Cell Carcinoma Differ From Patients Treated in Real-World Practice.

Mitchell AP, Harrison MR, Walker MS, George DJ, Abernethy AP, Hirsch BR.

J Oncol Pract. 2015 Sep 1. pii: JOP.2015.004929. [Epub ahead of print]

PMID:
26330533
10.

Insulin and IGFs in renal cancer risk and progression.

Solarek W, Czarnecka AM, Escudier B, Bielecka ZF, Lian F, Szczylik C.

Endocr Relat Cancer. 2015 Oct;22(5):R253-64. doi: 10.1530/ERC-15-0135. Review.

PMID:
26330483
11.

Does postoperative radiation therapy impact survival in non-metastatic sarcomatoid renal cell carcinoma? A SEER-based study.

Eminaga O, Akbarov I, Wille S, Engelmann U.

Int Urol Nephrol. 2015 Sep 2. [Epub ahead of print]

PMID:
26329746
12.

Quiz. Correct answer to the quiz. Check your diagnosis. Clear cell papillary renal cell carcinoma.

Joseph K, Liu KW, Chang IW.

Pol J Pathol. 2015 Jun;66(2):202-5.

PMID:
26328282
13.

Combination treatment with hypoxia-activated prodrug evofosfamide (TH-302) and mTOR inhibitors results in enhanced antitumor efficacy in preclinical renal cell carcinoma models.

Sun JD, Ahluwalia D, Liu Q, Li W, Wang Y, Meng F, Bhupathi D, Matteucci MD, Hart CP.

Am J Cancer Res. 2015 Jun 15;5(7):2139-55. eCollection 2015.

PMID:
26328245
14.

Immune Checkpoint Blockade: A New Paradigm in Treating Advanced Cancer.

Kreamer KM.

J Adv Pract Oncol. 2014 Nov-Dec;5(6):418-31. Review.

PMID:
26328216
15.

The relationship between histopathology and age factor in patients who were operated for renal masses.

Yıkılmaz TN, Baş O, Arık Aİ, Hızlı F, Başar H.

Turk J Urol. 2015 Jun;41(2):57-60. doi: 10.5152/tud.2015.54521.

PMID:
26328202
16.

Impact of preoperative radiological and postoperative pathological findings on survival of patients after radical nephrectomy performed with the indication of renal cell carcinoma.

Şimşek A, Küçüktopcu O, Akbulut F, Özgör F, Küçüktopcu E, Savun M, Berberoğlu Y, Gürbüz G.

Turk J Urol. 2015 Mar;41(1):1-6. doi: 10.5152/tud.2015.78800.

PMID:
26328189
17.

Renal cell carcinoma arising in ipsilateral duplex system.

Mohan H, Kundu R, Dalal U.

Turk J Urol. 2014 Sep;40(3):185-8. doi: 10.5152/tud.2014.93708.

PMID:
26328175
18.

Overexpression of CIP2A in clear cell renal cell carcinoma promotes cellular epithelial-mesenchymal transition and is associated with poor prognosis.

Tang Q, Wang Q, Zeng G, Li Q, Jiang T, Zhang Z, Zheng W, Wang K.

Oncol Rep. 2015 Aug 21. doi: 10.3892/or.2015.4217. [Epub ahead of print]

PMID:
26327467
19.

Magnetic resonance imaging of pancreatic metastases from renal cell carcinoma.

Sikka A, Adam SZ, Wood C, Hoff F, Harmath CB, Miller FH.

Clin Imaging. 2015 Jul 17. pii: S0899-7071(15)00173-4. doi: 10.1016/j.clinimag.2015.07.012. [Epub ahead of print] Review.

PMID:
26324216
20.

Silibinin induces apoptosis through inhibition of the mTOR-GLI1-BCL2 pathway in renal cell carcinoma.

Ma Z, Liu W, Zeng J, Zhou J, Guo P, Xie H, Yang Z, Zheng L, Xu S, Wang X, Chang LS, He D, Li L.

Oncol Rep. 2015 Aug 26. doi: 10.3892/or.2015.4224. [Epub ahead of print]

PMID:
26323996
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk